RESEARCH COMMUNICATIONS OF THE 28th ECVIM-CA CONGRESS

Ninety‐four dogs were included: median age was 9.7 years (range 3.9‐15) and median body weight 27.25 kg (range 4.8‐54.5). All patients underwent splenectomy followed by adjuvant chemotherapy: 50 dogs received anthracycline‐based protocols (40 doxorubicin [DOX], 5 epirubicin [EPI], 5 pegylated liposomal encapsulated doxorubicin [PG‐DOX]), 20 dogs received MC (18 cyclophosphamide, 2 chlorambucil) and 24 dogs received EPI (13), DOX (10) or PG‐DOX (1), followed by MC once the protocol ended (AMC group). The overall MST was 193 days (range 47‐3352) and the overall median TTP was 131 days (range 27‐909). The MST was 149 days for the AC group (range 47‐3352), 225 days for the MC group (range 57‐911) and 338 days for the AMC group (range 79‐1623). Survival was significantly longer in the AMC group vs the AC group (p= 0.0029) as well as TTP (183 vs 125 days, p=0.029), although no difference could be found between the MC group vs the AC or AMC group. Dogs receiving > 3 treatments with anthracyclines in the AMC vs the AC group survived significantly longer (338 vs 172 days, p=0.0015). No other factors appeared to affect survival or TTP.